PURPOSE/ OBJECTIVES: We analyzed outcomes after stereotactic ablative body radiotherapy for oligometastatic (1-5 metastatic foci) head-and-neck squamous cell carcinoma (OM-HNSCC). MATERIALS/ METHODS: We reviewed patients treated between 2012 and 2016. Endpoints included overall survival (OS), distant progression, and treated-metastasis local control (TM-LC). RESULTS: We analyzed 27 patients with 60 primarily metachronous metastases (81.5%). Median follow-up was 1.6 years (0.2-5.2). Median time from diagnosis to treatment was 1.1 years (0.08-8.5). Overall, 44.4% had solitary, 44.4% had 2-3, and 11.1% had >3 metastases; most metastases were in the lung (44 of 60 metastases). Median OS was 1.9 years; at 1 and 2 years, 78% and 43% were alive (14% without disease progression). Median time to progression was 0.5 years. The 1-year and 2-year TM-LC rates were 75% and 57%. CONCLUSIONS: OS is encouraging and disease-free survival remains poor; nevertheless, patients with OM-HNSCC may represent a more favorable subset of patients with metastatic HNSCC.
PURPOSE/ OBJECTIVES: We analyzed outcomes after stereotactic ablative body radiotherapy for oligometastatic (1-5 metastatic foci) head-and-neck squamous cell carcinoma (OM-HNSCC). MATERIALS/ METHODS: We reviewed patients treated between 2012 and 2016. Endpoints included overall survival (OS), distant progression, and treated-metastasis local control (TM-LC). RESULTS: We analyzed 27 patients with 60 primarily metachronous metastases (81.5%). Median follow-up was 1.6 years (0.2-5.2). Median time from diagnosis to treatment was 1.1 years (0.08-8.5). Overall, 44.4% had solitary, 44.4% had 2-3, and 11.1% had >3 metastases; most metastases were in the lung (44 of 60 metastases). Median OS was 1.9 years; at 1 and 2 years, 78% and 43% were alive (14% without disease progression). Median time to progression was 0.5 years. The 1-year and 2-year TM-LC rates were 75% and 57%. CONCLUSIONS: OS is encouraging and disease-free survival remains poor; nevertheless, patients with OM-HNSCC may represent a more favorable subset of patients with metastatic HNSCC.
Authors: Steven Borson; Yongli Shuai; Barton F Branstetter; Marci Lee Nilsen; Marion A Hughes; Moon Fenton; Mark Kubik; Shaum Sridharan; David A Clump; Heath D Skinner; Jonas T Johnson; Simion I Chiosea; James Ohr; Umamaheswar Duvvuri; Seungwon Kim; Katie S Traylor; Robert Ferris; Dan P Zandberg Journal: Laryngoscope Investig Otolaryngol Date: 2022-05-06
Authors: Thomas Weissmann; Daniel Höfler; Markus Hecht; Sabine Semrau; Marlen Haderlein; Irina Filimonova; Benjamin Frey; Christoph Bert; Sebastian Lettmaier; Konstantinos Mantsopoulos; Heinrich Iro; Rainer Fietkau; Florian Putz Journal: Radiat Oncol Date: 2021-03-31 Impact factor: 3.481
Authors: Ciro Franzese; M Badalamenti; A Teriaca; A De Virgilio; G Mercante; R Cavina; D Ferrari; A Santoro; G Spriano; M Scorsetti Journal: J Cancer Res Clin Oncol Date: 2021-01-20 Impact factor: 4.553